PGN EDO51
Alternative Names: EDO-51; PGN-EDO23; PGN-EDO51Latest Information Update: 05 Aug 2024
At a glance
- Originator Pepgen Corporation
- Class Antisense oligonucleotides; Drug conjugates; Morpholines; Peptide drug conjugates; Protein-drug conjugates
- Mechanism of Action Dystrophin expression stimulants; RNA splicing modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Duchenne muscular dystrophy
Most Recent Events
- 30 Jul 2024 Adverse events and pharmacodynamics data from a phase -II CONNECT1-EDO51 trial in Duchenne muscular dystrophy released by PepGen
- 14 Mar 2024 Updated pharmacodynamics data from a phase I trial (In volunteers) released by Pepgen Corporation
- 13 Mar 2024 PGN ED051 receives rare pediatric disease designations from the FDA for Duchenne Muscular Dystrophy